Valuation, Estimates and Model Methodology versus Stock Ranking

• Reg AC, Analysts Certification
• Ethics
• Regulatory Disclosure
• Legal Disclaimer
• Estimates, Models and Valuation Methodology
• Company Specific Disclosure
• Investment Suitability
• Research Dissemination
• Valuation, Estimates and Model Methodology versus Stock Ranking
• Disclosures Supporting Reporting
• Transparency of Analyst's Performance and Compensation for Product and Services Disclosures
•  

 In these current volatile market times; Scimitar has stepped back from making specific price targets. Valuation should be understood in terms of an objective quantitative model and a comprehensive qualitative explanation that enlightens investors to expectation and potential.

Scimitar prudently performs analysis and creates quantitative models and estimates derived from our own research and due diligence without any assistance from the/any represented company. Scimitar’s estimates and models reflect "our" current judgment only; they are neither all-inclusive nor can they be guaranteed. "Our" analysis and models are subject to change based on share pricing, share/capitalization increases or decreases, regulatory status and certainly market conditions. Projecting the valuation of emerging healthcare companies can be truly "inexact".

Reiterating, "NO" part of our compensation is related to the specific valuation recommendations or views contained in this review.